新药啥时估计能批准上_老虎社区_美港股上老虎

Steven16
2023-03-09

新药啥时估计能批准上市？

Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb

Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the

Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":627248985,"tweetId":"627248985","gmtCreate":1678375143747,"gmtModify":1678375145413,"author":{"id":3433494838648625,"idStr":"3433494838648625","authorId":3433494838648625,"authorIdStr":"3433494838648625","name":"Steven16","avatar":"https://static.tigerbbs.com/60af47707be9d6bacdbeb4efb27ae9f5","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>新药啥时估计能批准上市？</p></body></html>","htmlText":"<html><head></head><body><p>新药啥时估计能批准上市？</p></body></html>","text":"新药啥时估计能批准上市？","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/627248985","repostId":2317912071,"repostType":2,"repost":{"id":"2317912071","kind":"highlight","pubTimestamp":1678155949,"share":"https://www.laohu8.com/m/news/2317912071?lang=&edition=full","pubTime":"2023-03-07 10:25","market":"us","language":"en","title":"Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb","url":"https://stock-news.laohu8.com/highlight/detail?id=2317912071","media":"Seeking Alpha","summary":"Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the","content":"<html><head></head><body><p>Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will provide up to $130M in gross proceeds to Unicycive through a private placement, including initial upfront funding of $30M.</p><p><img src=\"https://static.tigerbbs.com/62a2bcdd1a2f8f9b59e98e4bebfa8481\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>The company remains on track to file a New Drug Application (NDA) for Renazorb marketing approval with the FDA in mid-year.</p><p>Proceeds from the offering will be used to support the Company’s NDA submission of Renazorb for the treatment of hyperphosphatemia in the U.S. and, if approved, for the commercial launch of Renazorb in the U.S.</p><p>The funding is being led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and is supported by existing investors Nantahala Capital Partners and Rosalind Advisors. Gaurav Aggarwal, M.D., Managing Director of Vivo Capital, will join the Unicycive Board of Directors.</p><p>Pursuant to the securities purchase agreement, the Company will issue to purchasers (i) $30M in shares of Series A Convertible Preferred Stock and (ii) three tranches of warrants exercisable for convertible preferred stock.</p><p>Shares of Series A Convertible Preferred Stock will be issued at a price of $1,000.00 per share.</p><p>In December 2022, Unicycive announced that the primary endpoint was met in its bioequivalence study comparing Renazorb to Fosrenol.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-07 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will ...</p>\n\n<a href=\"https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","UNCY":"Unicycive Therapeutics, Inc."},"source_url":"https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2317912071","content_text":"Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will provide up to $130M in gross proceeds to Unicycive through a private placement, including initial upfront funding of $30M.The company remains on track to file a New Drug Application (NDA) for Renazorb marketing approval with the FDA in mid-year.Proceeds from the offering will be used to support the Company’s NDA submission of Renazorb for the treatment of hyperphosphatemia in the U.S. and, if approved, for the commercial launch of Renazorb in the U.S.The funding is being led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and is supported by existing investors Nantahala Capital Partners and Rosalind Advisors. Gaurav Aggarwal, M.D., Managing Director of Vivo Capital, will join the Unicycive Board of Directors.Pursuant to the securities purchase agreement, the Company will issue to purchasers (i) $30M in shares of Series A Convertible Preferred Stock and (ii) three tranches of warrants exercisable for convertible preferred stock.Shares of Series A Convertible Preferred Stock will be issued at a price of $1,000.00 per share.In December 2022, Unicycive announced that the primary endpoint was met in its bioequivalence study comparing Renazorb to Fosrenol.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1284,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}